SCHEMBL5541355

SCHEMBL5541355

[CH2]c1ccccc1NC(=O)OCC

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.62
HPGD P15428 2/20 0.62
CYP1A2 P05177 2/20 0.56
CYP2C19 P33261 2/20 0.56
CYP2C9 P11712 1/20 0.56
SMN1; SMN2 Q16637 2/20 0.54
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
NLRP3 Q96P20 3/20 0.51
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
CRHBP P24387 1/20 0.50
CRHR2 Q13324 1/20 0.50
MAOB P27338 1/20 0.50
HSD17B10 Q99714 2/20 0.49
KDM4E B2RXH2 2/20 0.49
LMNA P02545 1/20 0.49
MAPT P10636 1/20 0.49
MAPK1 P28482 1/20 0.49
GLA P06280 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28401182 0.87 ALDH1A1 (0.72) ALDH1A1HPGDCYP1A2CYP2C19CYP2C9
SCHEMBL3930318 0.84 SMN1; SMN2 (0.66) ALDH1A1HPGDCYP1A2CYP2C19CYP2C9
SCHEMBL3934010 0.83 SMN1; SMN2 (0.60) ALDH1A1HPGDCYP1A2CYP2C19SMN1; SMN2
SCHEMBL30593915 0.82 NPC1 (0.71) ALDH1A1HPGDCYP1A2CYP2C19CYP2C9
SCHEMBL69360 0.82 NPC1 (0.71) ALDH1A1HPGDCYP1A2CYP2C19CYP2C9
SCHEMBL94680 0.82 HPGD (0.50) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL7257115 0.81 ALDH1A1 (0.64) ALDH1A1HPGDCYP1A2CYP2C19CYP2C9
SCHEMBL1400826 0.81 ALDH1A1 (0.64) ALDH1A1HPGDCYP1A2CYP2C19CYP2C9
SCHEMBL9069395 0.81 ALDH1A1 (0.64) ALDH1A1HPGDCYP1A2CYP2C19CYP2C9
SCHEMBL9342000 0.80 ALDH1A1 (0.78) ALDH1A1HPGDCYP1A2CYP2C19CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ALDH1A1 355/4885HPGD 3159/4885CYP1A2 659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.